Hikma were added to the Emertat’s portfolio

Hikma Pharmaceuticals is a multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products. It was founded in Amman, Jordan in 1978 by Samih Darwazah. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.

Hikma Pharmaceutical’s operations span 29 manufacturing plants in 11 countries: United States, Portugal, Italy, Jordan, Saudi Arabia, Algeria, Germany, Egypt, Morocco, Tunisia, and Sudan.

Hikma’s branded business segment comprises the development and sales of branded generics and in-licensed patented products in the MENA region. Hikma has 499 products in 1,256 dosage strengths. Top products include Actos, Amoclan, Blopress, Omnicef, Prograf, and Suprax. Hikma sells specialized injectable products in the US, Europe and MENA including argatroban, fentanyl, phenylephrine, robaxin, and iron gluconate. The company sells 200 products in 379 dosage forms and strengths. Hikma’s oral generic products are sold in the US and include such products as amoxicillin, cephalexin, doxycycline, methocarbamol, and prednisone.